Apontis Pharma AG
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, dylipidemia, secondary prophylaxis, and asthma, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany. Apont… Read more
Apontis Pharma AG (APPH) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.061x
Based on the latest financial reports, Apontis Pharma AG (APPH) has a cash flow conversion efficiency ratio of -0.061x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.94 Million) by net assets (€31.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Apontis Pharma AG - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Apontis Pharma AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Apontis Pharma AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apontis Pharma AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Linz Textil Holding AG
VI:LTH
|
0.059x |
|
Forge Group Inc.
PINK:FIGP
|
0.017x |
|
EE-HWA Construction Co. Ltd
KQ:001840
|
-0.290x |
|
Community Investors Bancorp Inc
PINK:CIBN
|
0.059x |
|
Chuang's China Investments Limited
F:CUG
|
0.046x |
|
Signal Advance Inc
PINK:SIGL
|
0.023x |
|
Sun Peak Metals Corp
OTCQB:SUNPF
|
-0.055x |
|
SaintMed Public Company Limited
BK:SMD
|
0.073x |
Annual Cash Flow Conversion Efficiency for Apontis Pharma AG (2019–2024)
The table below shows the annual cash flow conversion efficiency of Apontis Pharma AG from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €31.02 Million | €-2.90 Million | -0.094x | +77.54% |
| 2023-12-31 | €30.26 Million | €-12.60 Million | -0.416x | -257.05% |
| 2022-12-31 | €41.57 Million | €11.02 Million | 0.265x | +214.37% |
| 2021-12-31 | €40.71 Million | €3.43 Million | 0.084x | -79.90% |
| 2020-12-31 | €3.46 Million | €1.45 Million | 0.420x | +917.97% |
| 2019-12-31 | €4.64 Million | €-238.07K | -0.051x | -- |